ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA

Business Wire · 03.07.2025, 19:35 Uhr

Regulatory News:

Under the liquidity contract entered into by ABIONYX Pharma (Paris:ABNX) with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:

Number of shares: 162,298
Cash balance: 86,279.52 ¬

During the 1^sthalf of 2025, a total of :

PURCHASE

223,631 shares

275,707.78 ¬

253 transactions

SALE

214,077 shares

272,643.70 ¬

226 transactions

As a reminder, at the half-yearly balance sheet date of December 31, 2024, the following assets were included in the liquidity account:

Number of shares: 152,744 shares
Cash balance: 90,498.64 ¬

When the liquidity contract was set up, the following resources were made available:

Number of shares: 131,000 shares
Cash balance: 40,801.20 ¬

ANNEX H1 2025

Purchases

Sales

ABNX FP

number of
transactions

Number of
shares

Capital in
EUR

number of
transactions

Number of
shares

Capital in EUR

Total

253

223,631

275,707.78

226

214,077

272 ,643.696

20250101

0,00

20250102

1,20

20250103

4 731

5 598,24

1,20

20250106

2 151

2 555,39

1,19

20250107

2 091

2 475,76

2,41

20250108

1,21

16 781

20 838,45

20250109

1,28

4 091

5 261,22

20250110

6 674

8 375,50

1,30

20250113

2 321

2 915,20

1,28

20250114

2 251

2 827,26

1,26

20250115

2 283

2 834,77

1 364

1 732,25

20250116

2 181

2 708,83

68,58

20250117

1,27

12 861

16 681,79

20250120

2 411

3 134,32

4 051

5 396,12

20250121

5 141

6 583,61

1,29

20250122

2 391

3 003,11

1,27

20250123

2 321

2 910,53

125,61

20250124

2 251

2 827,28

3,85

20250127

3 001

3 731,25

1,25

20250128

1,24

20250129

3 726

4 523,13

1,24

20250130

300

362,40

1,21

20250131

19,30

8 891

11 103,15

20250203

3 141

3 830,03

90,00

20250204

2 251

2 710,21

1,21

20250205

1,22

2,44

20250206

2 181

2 630,31

1,23

20250207

2 131

2 544,42

1,20

20250210

1,22

2,44

20250211

1,20

20250212

1,20

6 289

7 736,41

20250213

3 011

3 659,43

2,49

20250214

1,23

2,46

20250217

250

300,50

4 441

5 480,40

20250218

1,24

4 329

5 463,59

20250219

3 201

3 941,54

392

494,68

20250220

1,33

15 961

21 228,13

20250221

1,31

738

972,68

20250224

3 621

4 697,72

1,32

20250225

1,33

11 351

15 354,69

20250226

3 811

5 134,77

3 591

4 962,95

20250227

3 821

5 140,51

1,35

20250228

5 691

7 466,21

1,35

20250303

1,30

12 891

17 168,66

20250304

6 181

8 071,89

2,69

20250305

2,54

1 559

2 023,55

20250306

2 921

3 727,21

1,29

20250307

3 871

4 913,61

1,27

20250310

3 721

4 715,77

1,27

20250311

5 571

6 855,74

1,26

20250312

1,24

20250313

424

517,30

4 051

5 072,04

20250314

3 571

4 439,97

1,25

20250317

2 561

3 129,56

1,24

20250318

1,24

20250319

2 481

3 031,78

1,22

20250320

2 411

2 941,43

4 231

5 297,39

20250321

1,26

19 891

25 919,78

20250324

3 627

4 672,00

972

1 281,10

20250325

2 901

3 690,09

1,29

20250326

1,29

20250327

1,28

20250328

1,28

20250331

1 862

2 346,13

1,27

20250401

9 031

11 067,11

1,27

20250402

5 341

6 540,66

1,24

20250403

3 301

4 051,43

1,23

20250404

7 581

9 022,58

1,24

20250407

10 871

12 406,55

1,19

20250408

1 338

1 493,23

9 741

11 244,94

20250409

4 202

4 770,74

1,14

20250410

1,18

13 821

16 335,50

20250411

2 451

2 857,87

1,17

20250414

911

1 060,43

2,38

20250415

2 351

2 741,29

1,19

20250416

640

744,96

1,16

20250417

1,19

2 231

2 659,35

20250418

0,00

20250421

0,00

20250422

1,20

4 481

5 386,40

20250423

1,19

4 321

5 280,47

20250424

1,23

413

508,82

20250425

1,21

20250428

1,23

249

306,27

20250429

2,44

1,23

20250430

1 865

2 256,68

1,24

20250501

0,00

20250502

1,22

2 071

2 551,46

20250505

10 811

12 763,44

1,24

20250506

3 021

3 629,31

2,46

20250507

1,23

20250508

1,21

20250509

1,23

20250512

2 191

2 629,20

1,20

20250513

1,23

4,93

20250514

1,23

20250515

1,23

20250516

2 061

2 493,83

1,23

20250519

1,23

20250520

1,21

9 071

11 364,29

20250521

1,24

2,49

20250522

1,24

4 371

5 455,20

20250523

1,26

8 381

10 768,00

20250526

1,30

2 001

2 601,30

20250527

1,31

7 871

10 396,13

20250528

1,33

3 579

4 767,23

20250529

6 071

7 774,61

1,29

20250530

1,29

20250602

1,30

474

619,98

20250603

1,31

20250604

3 771

4 839,51

1,29

20250605

1,26

20250606

1,28

20250609

1,28

20250610

1,29

1 951

2 520,69

20250611

3 002

3 833,87

1,30

20250612

3 621

4 589,10

1,30

20250613

3 511

4 400,52

1,26

20250616

300

372,00

1,24

20250617

1,25

20250618

961

1 180,13

1,25

20250619

1,25

20250620

2 491

3 058,95

1,23

20250623

3 301

4 031,62

1,22

20250624

1,23

20250625

2 361

2 852,09

1,21

20250626

1,23

20250627

1,23

20250630

4 761

5 678,38

1,20

About ABIONYX Pharma

ABIONYX Pharma is a new-generation biotechnology company whose aim is to contribute to healthcare through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new apoA-1 vectors used for targeted drug delivery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250703756010/en/

NewCap
Investor Relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media Relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15